What type of study is this?

September 5, 2025Blood AdvancesOpen Access

Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia

View Full Paper

Ask AI

Bookmark

Patients receiving cilta-cel had a median overall survival of over 23 months, improving treatment outcomes.
The one-year cumulative incidence of progression or death was 37.5% with cilta-cel versus 100% with ide-cel.
Overall median progression free survival for PCL patients treated with CAR-T was 9.0 months.
This multicenter study demonstrates BCMA-directed CAR-T as a safe and feasible option for improving outcomes in plasma cell leukemia.

No takes yet. Share an insight, caveat, or question.

Multicenter analysis reveals BCMA-directed CAR-T improves survival in plasma cell leukemia, indicating a potential new treatment standard.

Fortuna et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Multicenter analysis reveals BCMA-directed CAR-T improves survival in plasma cell leukemia, indicating a potential new treatment standard.